You searched for "intracameral"

598 results found

Moorfields: Implementing a non-medical intravitreal injection service Nov

This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services.

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection

In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...

Intravitreal Bevacizumab for the prevention of postoperative proliferative vitreoretinopathy in high-risk patients

This single- centre observational retrospective study was conducted to evaluate the effect of intravitreal injection of bevacizumab at the time surgery for rhegmatogenous retinal detachment (RRD) repair on postoperative proliferative vitreoretinopathy (PVR) in patients at high risk selected by laser...

Autofluorescence patterns in subretinal haemorrhages associated with neovascular age-related macular degeneration

The aim of this retrospective study was to describe the surgical results and fundus autofluorescence (FAF) patterns occurring in sub-macular haemorrhage (SMH) of duration <60 days in age-related macular degeneration (AMD). Notes from 39 eyes of 39 patients with SMH,...

IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis

This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...

Oct/Nov 2019 Quiz

History A 62-year-old female patient was referred for rapid growth of a left periorbital soft tissue lesion with proptosis. Her past medical history included: hypertension, hyperlipidaemia and bipolar disorder. On examination: vision in the affected eye was hand movements, right...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Post hoc analysis of the CANTREAT randomised trial

CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...